In the BioHarmony Drug Report Database
Arazlo, Avage, Fabior, Tazorac (tazarotene) is a small molecule pharmaceutical. Tazarotene was first approved as Arazlo on 1997-06-13. It is used to treat acne vulgaris and psoriasis in the USA. The pharmaceutical is active against retinoic acid receptor beta, retinoic acid receptor alpha, and retinoic acid receptor gamma. In addition, it is known to target chemokine-like receptor 1 and G-protein coupled receptor 1. Tazorac’s patent is valid until 2030-02-24 (FDA).
Image (chem structure or protein)